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 BACKGROUND:  
Lens epithelium derived growth factor interaction inhibitors (LEDGINs) 
form an emerging class of allosteric integrase inhibitors, targeting the 
cellular co-factor of integrase, i.e. LEDGF/p75. Only few data are 
available on LEDGF/p75 expression and its genetic variability in HIV 
infected patients. The present study evaluated whether genetic variation 
in the LEDGF/p75 gene and mRNA/protein expression levels influence 
HIV disease progression.  
METHODS & RESULTS:  
Patients: Samples were derived from a therapy-naive patient cohort from 
Ghent University Hospital and from long-term-non-progressor patients as 
kindly provided by the HIV Biobank (Spanish AIDS Research Network, 
RIS). Elite controllers are defined as therapy-naive long-term-non-
progressors (LTNP) with undetectable viral load, LTNP viremic controllers 
have a viral load below 2000 copies/ml without therapy in 75% of the 
measurements, LTNP viremic non controllers are therapy-naive and 
harbor a viral load >2000 copies/ml. Normal progressors are non-LTNP 
with a CD4 decline less than 100 cells/µl*year and rapid progressors are 
non-LTNP patients with CD4 decline of more than 100 cells/µl*year. 
SNP detection: A genomic scan of the coding region (including intronic 
regions near the exon-intron boundary and 3’UTR) of LEDGF/p75 was 
performed with high resolution melting (HRM) curve analysis and Sanger 
sequencing to identify single nucleotide polymorphisms (SNPs). 24 SNPs 
were identified, of which 5 in the coding region, 17 in the non-coding 
regions and 3’UTR. In addition to these, two known tagSNPs were 
included. Only the SNPs that were correlated with disease progression, 
average viral load or CD4 slope are described (Fig. 1).  
Fig. 1: Illustration of the DNA, mRNA and protein of LEDGF/p75. Intronic sites in the 
DNA are grey, and the positions of the SNPs that are discussed are marked. 
LEDGF mRNA expression:  
mRNA expression levels were 
determined using RT-qPCR with 
validated reference genes for 
normalization. This revealed a 
stable expression of the mRNA in 
most patient samples (Fig. 2). 
Table 1: Patient characteristics 
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rs2737828  
This intronic SNP was under-
represented in Caucasian HIV patients 
(P<0.0001) compared to healthy 
Caucasians as published in HapMap. In 
addition, the presense of this SNP 
tends to correlate with lower LEDGF/
p75 expression (P=0.053), but not with 
disease progression markers.  
Gene 
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Protein 
Fig. 2: LEDGF/p75 mRNA expression in 
all patients 
rs16933270 rs2737835  
This SNP, mainly present in 
Africans was correlated with CD4 
decline (P= 0.020). 
This SNP tends to be associated 
with slower CD4 decline in 
Caucasian non controllers 
(P=0.058). 
Western Blotting:         
A high variability of LEDGF/p75 
expression was observed using β-
ACTIN as loading control. This 
variability was also observed in 
biological replicate samples and 
was independent of LEDGF/p75 
mRNA levels (Fig. 3). 
Association of LEDGF/p75 SNPs with disease progression 
The SNPs in the coding region were low-abundant and did not correlate  
with disease progression nor with LEDGF/p75 expression. For most of 
the intronic and 3’UTR SNPs found, no correlation could be determined 
with either CD4 slope, viral load or LEDGF/p75 expression. However, for 
three SNPs, a possible association between SNP presence and HIV 
disease were found, i.e. rs2737828, rs2737835 and rs16933270. 
DISCUSSION:  
This is the first report on SNP profiling in the entire coding region of the 
LEDGF/p75 gene in HIV infected patients. The results reveal that the 
coding region contains little variation. Certain rare variants of LEDGF/p75 
intronic or 3’UTR region can be associated with HIV disease susceptibility 
or disease progression. 
The variant rs2737835, present in Caucasian patients, tends to associate 
with slower CD4 decline. rs16933270, mainly present in African patients  
significantly correlated with CD4 decline. These date indicate that genetic 
variations in LEDGF/p75 can influence disease progression.  
The finding that SNP rs2737828 was significantly underrepresented in 
Caucasian HIV patients in relation to the expected frequency according to 
HapMap, suggests that this SNP might influence disease susceptibility. 
Interestingly, except for rs2737828, there was no correlation between the 
presence of these variants and differential expression at the mRNA and 
protein levels. The high variety of protein expression that is not correlated 
with LEDGF/p75 mRNA expression suggests that post transcriptional 
modifications are important for protein expression. This might have 
implications for the pharmacodynamic impact of LEDGIN in vivo. 
CONCLUSIONS:  
This study supports the hypothesis that genetic variation in the host 
factors LEDGF/p75 can influence HIV disease progression.  
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Ghent  
Cohort 
N=187 
RIS  
Cohort 
N=138 
Overall 
N=325 
Ethnicity, N (%) African 34 (18,2) 0 (0) 34 (10,5) 
  
Caucasian 153 (81,2) 138 (100) 291 (89,5) 
Disease progression N (%) LTNP - Elite controller 6 (3,2) 42 (30,4) 48 (14,8) 
  
LTNP - Viremic controller 16 (8,6) 47 (34,1) 63 (19,4) 
  
LTNP - Non controller 17 (9,1) 49 (35,5) 66 (20,3) 
  
Normal progressor 113 (60,4) 0 (0,0) 113 (34,8) 
  
Rapid progressor 35 (18,7) 0 (0,0) 35 (10,8) 
Fig. 3: Western blot on patient samples, 
1,2,3-4,6,9: normal progressors, 1&2 
and 8&9: biological replicates, 3: viremic 
controller, 5&7 elite controllers 
